All In Biotech

Drug Trial Radar · NCT00769886

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Oct 2008

Primary completion

Dec 2008

Study completion Jun 2009

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 9, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

  • Ketotifen/naphazolineDrug

    One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.

  • KetotifenDrug

    One drop of Ketotifen in study eye at visit 3 and visit 4.

  • NaphazolineDrug

    One drop of naphazoline in study eye at vist 3 and visit 4.

  • VehicleDrug

    One drop of vehicle in study eye at visit 3 and visit 4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular ItchingTime frame: 3, 5, and 7 minutes post challenge at 14 days
  2. Conjunctival HyperemiaTime frame: 7, 15, and 20 minutes post challenge at 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ophthalmic Research Consultants, Inc.

    North Andover, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.